Table 1.
Demographic and baseline clinical data of patients treated with eltrombopag.
| Total, n° | 71 |
| Gender, n° (%) | |
| M | 31 (44%) |
| F | 40 (56%) |
| Age at onset of ITP, years | |
| Median (range) | 7 (1–17) |
| Second-line therapies prior eltrombopag, n° (%) | 38 (54%) |
| Cyclosporine | 1 (1%) |
| Mycophenolate mofetil | 28 (39%) |
| Rituximab | 15 (21%) |
| Sirolimus | 12 (17%) |
| Splenectomy | 2 (3%) |
| ITP duration before the first dose, years | |
| Median (range) | 2 (1–14) |
| Age at the start of eltrombopag, years | |
| Median (range) | 12 (3–17) |
| Median starting dose|, mg | |
| Median (range) | 50 (12,5–75) |
| Baseline platelet count, × 109/L | |
| Median (range) | 10 (1–51) |
| Patients with a platelet count of at least 30 × 109/L, n°(%) | 12 (17%) |